Alekshun M N, Levy S B
Paratek Pharmaceuticals Inc., Boston, MA 02111, USA.
Biochem Pharmacol. 2006 Mar 30;71(7):893-900. doi: 10.1016/j.bcp.2005.12.040. Epub 2006 Feb 7.
A battle to control and curtail bacterial infectious diseases is being waged in our hospitals and communities through antibiotic therapies and vaccines targeting specific species. But what effects do these interventions have on the epidemiology of infections caused by the organisms that are part of our natural microbial flora? Gram-positive and gram-negative bacteria appear as new disease agents from among commensal flora. These include vancomycin resistant enterococci (VRE), community-associated methicillin resistant Staphylococcus aureus (CA-MRSA), non-vaccine invasive serotypes of Streptococcus pneumoniae, new strains of non-type b Haemophilus influenzae and multi-drug resistant Escherichia coli. These examples illustrate how clinical improvements and widespread use and misuse of antibiotics have pushed evolution, allowing normally non-pathogenic strains to become infectious disease threats to human health.
通过针对特定菌种的抗生素疗法和疫苗,一场控制和减少细菌性传染病的战斗正在我们的医院和社区中展开。但是,这些干预措施对作为我们自然微生物群落一部分的生物体所引起感染的流行病学有什么影响呢?革兰氏阳性菌和革兰氏阴性菌从共生菌群中成为新的病原体。这些包括耐万古霉素肠球菌(VRE)、社区获得性耐甲氧西林金黄色葡萄球菌(CA-MRSA)、肺炎链球菌的非疫苗侵袭性血清型、非b型流感嗜血杆菌的新菌株以及多重耐药大肠杆菌。这些例子说明了临床改善以及抗生素的广泛使用和滥用是如何推动进化的,使得原本无致病性的菌株成为对人类健康的传染病威胁。